Cancer Res (2023) 83 (8_Supplement): LB321. Citation Format: Elizabeth Donohue Vo, Yang W. Zhang, Dave Rominger, Jillian M. Silva, Yang J. Zhang, Greg Lee, John ...

You do not currently have access to this content.

Cancer Res (2025) 85 (8_Supplement_1): 841. Measurement of plasma and tumor concentrations were completed using standard extraction techniques with quantitation by LC-MS/MS methods. Target modulation ...

Annual Meeting 2026 AACR Journals Simultaneous Publications | American Association for Cancer Research AACR Annual Meeting 2026: AACR Journals’ Simultaneous Publications These AACR journal articles ...

Abstract. Previously, we reported on a series of highly potent, selective, and non-covalent CDK7 inhibitors that demonstrated antiproliferative activity against triple-negative breast cancer (TNBC) ...

NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio ® (avelumab), a ...

Annual Meeting 2025 AACR Journals Simultaneous Publications | American Association for Cancer Research AACR Annual Meeting 2025: AACR Journals’ Concurrent Publications These journal articles published ...

Cancer Immunol Res (2026) 14 (2_Supplement): A038.

Clin Cancer Res (2009) 15 (13): 4446–4452. Purpose: Multiplexing assay of biomarkers at the point-of-care is an elusive goal for molecular diagnostics. Experimental Design: Here, we report an ...

1Department of Pathology, NYU Grossman School of Medicine, New York, New York.

Abstract. Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: an EBCTCG meta-analysis of individual patient data from 12 randomised ...

In 2025, 2% of all manuscripts sent for peer review were submitted using the guaranteed peer review benefit. These manuscripts were high quality, with an acceptance rate above 50%, showing that the ...